

Martin Wagenmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7053355/publications.pdf>

Version: 2024-02-01

104
papers

4,332
citations

117625

34
h-index

123424

61
g-index

140
all docs

140
docs citations

140
times ranked

4254
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-5 synthesis is upregulated in human nasal polyp tissue. <i>Journal of Allergy and Clinical Immunology</i> , 1997, 99, 837-842.	2.9	317
2	Visual analogue scales (VAS): Measuring instruments for the documentation of symptoms and therapy monitoring in cases of allergic rhinitis in everyday health care. <i>Allergo Journal International</i> , 2017, 26, 16-24.	2.0	292
3	Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1141-1153.	10.7	263
4	EUFOR EA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 29-36.	2.9	178
5	EAACI Position paper on the standardization of nasal allergen challenges. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1597-1608.	5.7	161
6	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	5.7	160
7	The role of cytokines in infectious sinusitis and nasal polyposis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1998, 53, 2-13.	5.7	140
8	Guidelines on the management of IgE-mediated food allergies. <i>Allergo Journal International</i> , 2015, 24, 256-293.	2.0	129
9	Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper. <i>Clinical and Translational Allergy</i> , 2020, 10, 1.	3.2	110
10	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	2.9	103
11	Comparison of the secretory response of the nasal mucosa to methacholine and histamine. <i>Journal of Applied Physiology</i> , 1993, 74, 2661-2671.	2.5	90
12	Next-generation ARIA care pathways for rhinitis and asthma: a model for multimorbid chronic diseases. <i>Clinical and Translational Allergy</i> , 2019, 9, 44.	3.2	87
13	Validation of the MASK-rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control. <i>Clinical and Experimental Allergy</i> , 2017, 47, 1526-1533.	2.9	75
14	Emerging therapeutic options in fulminant invasive rhinocerebral mucormycosis. <i>Auris Nasus Larynx</i> , 2010, 37, 322-328.	1.2	70
15	Anatomic and physiologic considerations in sinusitis. <i>Journal of Allergy and Clinical Immunology</i> , 1992, 90, 419-423.	2.9	64
16	AluY-mediated germline deletion, duplication and somatic stem cell reversion in <i>UBE2T</i> defines a new subtype of Fanconi anemia. <i>Human Molecular Genetics</i> , 2015, 24, 5093-5108.	2.9	62
17	Electronic Clinical Decision Support System for allergic rhinitis management: MASK eCDSS. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1640-1653.	2.9	61
18	Proinflammatory Cytokines: Measurement in Nasal Secretion and Induction of Adhesion Receptor Expression. <i>International Archives of Allergy and Immunology</i> , 1995, 107, 106-108.	2.1	58

#	ARTICLE	IF	CITATIONS
19	Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA. <i>Allergo Journal International</i> , 2021, 30, 51-55.	2.0	55
20	Complications of sinusitis. <i>Journal of Allergy and Clinical Immunology</i> , 1992, 90, 552-554.	2.9	54
21	The time course of the bilateral release of cytokines and mediators after unilateral nasal allergen challenge. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2005, 60, 1132-1138.	5.7	54
22	Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (<sc>MACVIA</sc>â€•<sc>ARIA</sc>) â€•<sc>EIP</sc> on <sc>AHA</sc> Twinning Reference Site (<sc>GARD</sc> research demonstration project). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 77-92.	5.7	54
23	Elevated levels of interleukins IL-1 ^{Î²} , IL-6 and IL-8 in naturally acquired viral rhinitis. <i>European Archives of Oto-Rhino-Laryngology</i> , 1995, 252, S61-S63.	1.6	52
24	Comparison of the Nasal Release of IL-4, IL-10, IL-17, CCL13/MCP-4, and CCL26/eotaxin-3 in Allergic Rhinitis during Season and after Allergen Challenge. <i>American Journal of Rhinology and Allergy</i> , 2013, 27, 266-272.	2.0	52
25	<sc>ARIA</sc> pharmacy 2018 â€œAllergic rhinitis care pathways for community pharmacyâ€•. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1219-1236.	5.7	52
26	Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps. <i>International Forum of Allergy and Rhinology</i> , 2021, 11, 1087-1101.	2.8	48
27	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	3.2	47
28	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 168-190.	5.7	46
29	Realâ€•life assessment of chronic rhinosinusitis patients using mobile technology: The mySinusitisCoach project by EUFOREA. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2867-2878.	5.7	45
30	Update of the S2k guideline on the management of IgE-mediated food allergies. <i>Allergologie Select</i> , 2021, 5, 195-243.	3.1	42
31	The effect of terfenadine on unilateral nasal challenge with allergen. <i>Journal of Allergy and Clinical Immunology</i> , 1994, 93, 594-605.	2.9	38
32	Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic. <i>Allergologie Select</i> , 2020, 4, 53-68.	3.1	38
33	Cytokines and Adhesion Molecules in Allergic Rhinitis. <i>American Journal of Rhinology & Allergy</i> , 1998, 12, 3-8.	2.2	36
34	Squamous Cell Carcinomas of the Head and Neck in Fanconi Anemia: Risk, Prevention, Therapy, and the Need for Guidelines. <i>Klinische Padiatrie</i> , 2012, 224, 132-138.	0.6	35
35	Severe allergic reactions to the COVID-19 vaccine â€• statement and practical consequences. <i>Allergologie Select</i> , 2021, 5, 26-28.	3.1	33
36	Vascularised local and free flaps in anterior skull base reconstruction. <i>European Archives of Oto-Rhino-Laryngology</i> , 2013, 270, 899-907.	1.6	31

#	ARTICLE	IF	CITATIONS
37	Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. <i>Gene Therapy</i> , 2016, 23, 615-626.	4.5	30
38	Elevated levels of myeloperoxidase, pro-inflammatory cytokines and chemokines in naturally acquired upper respiratory tract infections. <i>European Archives of Oto-Rhino-Laryngology</i> , 2001, 258, 406-412.	1.6	29
39	Nasal levels of soluble IL-33, IL-2 and IL-16 in allergic rhinitis: inverse correlation trends with disease severity. <i>Clinical and Experimental Allergy</i> , 2013, 43, 1134-1143.	2.9	29
40	Cytokine Patterns and Endotypes in Acute and Chronic Rhinosinusitis. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 3.	5.3	29
41	COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologics) – A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology. <i>Allergologie Select</i> , 2021, 5, 140-147.	3.1	28
42	Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D ₂ . <i>Clinical and Experimental Allergy</i> , 1996, 26, 371-378.	2.9	27
43	RAD51C – A new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC). <i>Oral Oncology</i> , 2014, 50, 196-199.	1.5	27
44	Petasol butenoate complex (Ze 339) relieves allergic rhinitis-induced nasal obstruction more effectively than desloratadine. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 127, 1515-1521.e6.	2.9	26
45	The release of IL-31 and IL-13 after nasal allergen challenge and their relation to nasal symptoms. <i>Clinical and Translational Allergy</i> , 2012, 2, 13.	3.2	26
46	Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis. <i>Rhinology</i> , 2011, 49, 272-280.	1.3	26
47	Serum level and tissue expression of c-erbB-1 and c-erbB-2 proto-oncogene products in patients with squamous cell carcinoma of the head and neck. <i>Oral Oncology</i> , 2001, 37, 50-56.	1.5	25
48	Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement. <i>World Allergy Organization Journal</i> , 2020, 13, 100124.	3.5	25
49	Bilateral increases in histamine after unilateral nasal allergen challenge.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 155, 426-431.	5.6	24
50	Surgical management of retropharyngeal abscesses. <i>Acta Oto-Laryngologica</i> , 2009, 129, 1274-1279.	0.9	24
51	ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. <i>Clinical and Translational Allergy</i> , 2021, 11, e12014.	3.2	24
52	Allergen immunotherapy in the current COVID-19 pandemic: A position paper of AeDA, ARIA, EAACI, DGAKI and GPA. <i>Allergologie Select</i> , 2020, 4, 44-52.	3.1	23
53	Food allergy knowledge, attitudes and their determinants among restaurant staff: A cross-sectional study. <i>PLoS ONE</i> , 2019, 14, e0214625.	2.5	22
54	CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head/neck squamous cell carcinoma cells. <i>Oral Oncology</i> , 2021, 116, 105259.	1.5	22

#	ARTICLE	IF	CITATIONS
55	Onset and duration of inhibition of ipratropium bromide nasal spray on methacholine-induced nasal secretions. <i>Clinical and Experimental Allergy</i> , 1994, 24, 288-290.	2.9	21
56	An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial. <i>Clinical and Translational Allergy</i> , 2015, 6, 4.	3.2	16
57	Therapeutic Index (TIX) for intranasal corticosteroids in the treatment of allergic rhinitis.. <i>Rhinology</i> , 2011, 49, 272-280.	1.3	15
58	Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 160-168.	1.0	15
59	An intronic alteration of the fibroblast growth factor 10 gene causing ALSG-(aplasia of lacrimal and) Tj ETQq1 1 0.784314 rgBT /Overl	2.1	14
60	Is allergy immunotherapy with birch sufficient to treat patients allergic to pollen of tree species of the birch homologous group?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1327-1336.	5.7	13
61	Biologics for atopic diseases: Indication, side effect management, and new developments. <i>Allergologie Select</i> , 2021, 5, 1-25.	3.1	13
62	Radiomics in Head and Neck Cancer: Extracting Valuable Information from Data beyond Recognition. <i>Orl</i> , 2017, 79, 65-71.	1.1	11
63	Randomized immunotherapy trial in dual allergic patients using active allergen placebo as control. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1480-1489.	5.7	10
64	Effect of the tongue-in-groove technique on the smile form. <i>Rhinology</i> , 2020, 58, 626-628.	1.3	10
65	Effect of Terfenadine on Nasal Provocation. <i>International Archives of Allergy and Immunology</i> , 1993, 101, 311-317.	2.1	9
66	Squamous Cell Cancer and Human Papillomavirus Infection in Oral Lichen Planus: Case Report and Literature Review. <i>Dermatologic Surgery</i> , 2007, 33, 756-760.	0.8	9
67	COVID-19 vaccination and allergen immunotherapy (AIT) - A position paper of the German Society for Applied Allergology (AeDA) and the German Society for Allergology and Clinical Immunology (DGAKI). <i>Allergologie Select</i> , 2021, 5, 251-259.	3.1	9
68	A novel CD34-derived hinge for rapid and efficient detection and enrichment of CAR T cells. <i>Molecular Therapy - Oncolytics</i> , 2021, 23, 534-546.	4.4	9
69	Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design. <i>American Journal of Rhinology and Allergy</i> , 2022, 36, 788-795.	2.0	9
70	Update Leitlinie zum Management IgE-vermittelter Nahrungsmittelallergien - S2k-Leitlinie der DGAKI. <i>Allergologie</i> , 2021, 44, 488-541.	0.1	8
71	622 Increased production of type-2 and type1 cytokines in nasal polyps. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, S210.	2.9	7
72	Taking a Fresh Look at the Skull Base in Otorhinolaryngology With Web-Based Simulation. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 154.	2.2	7

#	ARTICLE	IF	CITATIONS
73	Unilateral nasal allergen challenge leads to bilateral release of prostaglandin D2. <i>Clinical and Experimental Allergy</i> , 1996, 26, 371-8.	2.9	7
74	Biomarkers in Allergic Airway Disease: Simply Complex. <i>Orl</i> , 2017, 79, 72-77.	1.1	6
75	Endotypes in Chronic Rhinosinusitis: Biomarkers Based on a Mechanistic Insight for Targeted Treatment?. <i>Orl</i> , 2017, 79, 78-84.	1.1	6
76	Allergen immunotherapy during the COVID-19 pandemic? A survey of the German Society for Allergy and Clinical Immunology. <i>Clinical and Translational Allergy</i> , 2022, 12, e12134.	3.2	6
77	Activin-A Is a Pro-Inflammatory Regulator in Type-2-Driven Upper Airway Disease. <i>International Archives of Allergy and Immunology</i> , 2018, 176, 15-25.	2.1	5
78	Visuelle Analogskalen (VAS) als Messinstrumente zur Dokumentation der Symptomatik und Therapiekontrolle einer allergischen Rhinitis in der Routineversorgung. <i>Allergologie</i> , 2018, 41, 364-374.	0.1	5
79	Mutational and Functional Analysis of FANCB as a Candidate Gene for Sporadic Head and Neck Squamous Cell Carcinomas. <i>Anticancer Research</i> , 2018, 38, 1317-1325.	1.1	5
80	Specific Immunotherapy Suppresses IL-1 β and IL-8 Levels in Nasal Secretions: A Possible Explanation for the Inhibition of Inflammatory Cell Migration. <i>Oto-rhino-laryngologia Nova</i> , 1997, 7, 31-39.	0.0	4
81	Optimized NGFR-derived hinges for rapid and efficient enrichment and detection of CAR T cells in vitro and in vivo. <i>Molecular Therapy - Oncolytics</i> , 2022, 26, 120-134.	4.4	4
82	Durchföhrung des nasalen Provokationstests bei Erkrankungen der oberen Atemwege – Positionspapier der Deutschen Gesellschaft für Allergologie und Klinische Immunologie (Sektion) Tj ETQq0 0 0 rg81/Overlock 10 Tf 50		
83	The checkpointkinase 2 (CHK2) 1100delC germ line mutation is not associated with the development of squamous cell carcinoma of the head and neck (SCCHN). <i>Journal of Negative Results in BioMedicine</i> , 2010, 9, 10.	1.4	2
84	Challenges in Histologic Diagnosis of Nonchordomatous Lesions of the Clivus. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015, 141, 745.	2.2	2
85	Nasal Provocation Testing. , 2009, , 1281-1294.		2
86	Precision medicine reaching out to the patients in allergology – a German-Japanese workshop report. <i>Allergologie Select</i> , 2021, 5, 162-179.	3.1	1
87	Der ELISPOT-Assay, eine hochsensitive Methode zur Untersuchung der Zytokinproduktion der Nasenschleimhaut. <i>Allergologie</i> , 2005, 28, 401-411.	0.1	1
88	MP29-02 (Dymista®) – Eine neue Behandlungsoption für die allergische Rhinitis. <i>Allergologie</i> , 2014, 37, 55-68.	0.1	1
89	Evaluating treatment Responses of dupilumab versus omalizumab in Type 2 patients: the EVEREST Trial. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, AB49.	2.9	1
90	Cytokine production in the sinus mucosa is correlated to clinical parameters of chronic sinusitis before and after sinus surgery. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S84-S84.	2.9	0

#	ARTICLE	IF	CITATIONS
91	Regulatory Cytokines In Chronic Rhinosinusitis With And Without Nasal Polyps. Journal of Allergy and Clinical Immunology, 2007, 119, S243.	2.9	0
92	Th2-Cytokines Dominate the Allergic Inflammation after Nasal Allergen Provocation while Chronic Natural Allergen Exposure also induces Th1-Cytokines. Journal of Allergy and Clinical Immunology, 2008, 121, S276-S276.	2.9	0
93	Analysis of TLR2, TLR4, TLR5, and TLR9 Polymorphisms in Chronic Rhinosinusitis (CRS). Journal of Allergy and Clinical Immunology, 2009, 123, S145-S145.	2.9	0
94	Nonallergic Rhinitis-Identifying Gaps in Research. Journal of Allergy and Clinical Immunology, 2011, 127, AB254-AB254.	2.9	0
95	Release Kinetics Of Soluble ST2 and Proinflammatory Cytokines In Allergic Rhinitis. Journal of Allergy and Clinical Immunology, 2014, 133, AB143.	2.9	0
96	Schwere allergische Reaktionen auf die Covid-19-Impfung – Stellungnahme und praktische Konsequenzen. Allergologie, 2021, 44, 7-8.	0.1	0
97	Health-Related Quality of Life Impairment Among Patients With Severe Chronic Rhinosinusitis With Nasal Polyps in the SINUS-24 Trial. Journal of Allergy and Clinical Immunology, 2021, 147, AB133.	2.9	0
98	COVID-19-Impfungen von allergischen Patienten im zeitlichen Zusammenhang mit einer Allergen-Immuntherapie (AIT) – Ein Positionspapier des –rzteverbandes Deutscher Allergologen (AeDA) und der Deutschen Gesellschaft f–r Allergologie und Klin. Allergologie, 2021, 44, 339-348.	0.1	0
99	Multimorbidit–t bei allergischer Rhinitis. Allergologie, 2021, 44, 22-30.	0.1	0
100	Biologika bei atopischen Erkrankungen: Indikationsstellung, Nebenwirkungsmanagement und neue Entwicklungen. Allergologie, 2021, 44, 54-80.	0.1	0
101	Ein Comeback f–r die Capsaicin- Therapie bei nicht-allergischer Rhinitis?. Allergologie, 2014, 37, 476-478.	0.1	0
102	Leitlinie zum Management IgE-vermittelter Nahrungsmittelallergien. Allergologie, 2016, 39, 302-344.	0.1	0
103	Unvertr–glichkeitsreaktionen und Allergien bei implantierbaren H–rsystemen. Allergologie, 2018, 41, 140-144.	0.1	0
104	Wir stellen uns vor: Sektion HNO der DGAKI. Allergologie, 2021, 44, 811-812.	0.1	0